Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 3
2006 1
2007 9
2008 6
2009 3
2010 2
2011 1
2012 1
2013 2
2014 1
2015 2
2016 2
2017 3
2019 2
2022 1
2023 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Unexpected cardiotoxicity in haematological bortezomib treated patients.
Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P. Enrico O, et al. Among authors: giulia c. Br J Haematol. 2007 Aug;138(3):396-7. doi: 10.1111/j.1365-2141.2007.06659.x. Epub 2007 Jun 11. Br J Haematol. 2007. PMID: 17561972 No abstract available.
Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease.
Benedetti E, Baratè C, Mavilia F, Bramanti E, Morganti R, Guerri V, Cervetti G, Capochiani E, Bertaggia I, Stella SM, Traverso G, Bruno B, Galimberti S. Benedetti E, et al. Among authors: cervetti g. J Clin Med. 2023 Feb 23;12(5):1772. doi: 10.3390/jcm12051772. J Clin Med. 2023. PMID: 36902559 Free PMC article.
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).
Cencini E, Romano I, Ghio F, Camerini C, Bertaggia I, Giachetti R, Mannelli L, Pirrotta MT, Navei GL, Ciceri M, Cervetti G, Sant'Antonio E, Simonetti F, Birtolo S, Puccini B, Bocchia M, Fabbri A. Cencini E, et al. Among authors: cervetti g. Ann Hematol. 2023 Apr;102(4):841-849. doi: 10.1007/s00277-023-05113-9. Epub 2023 Feb 3. Ann Hematol. 2023. PMID: 36735074
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
Carulli G, Baratè C, Marini A, Ottaviano V, Cervetti G, Fontanelli G, Guerrini F, Arici R, Guerri V, Di Paolo A, Polillo M, Ferreri MI, Galimberti S, Petrini M. Carulli G, et al. Among authors: cervetti g. Hematol Oncol. 2015 Dec;33(4):250-2. doi: 10.1002/hon.2156. Epub 2014 Sep 25. Hematol Oncol. 2015. PMID: 25256816 No abstract available.
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).
Cencini E, Palazzo M, Dardanis D, Lucco Navei G, Mannelli L, Zoi V, Mecacci B, Sordi B, Cervetti G, Rosati S, Nassi L, Bocchia M, Fabbri A. Cencini E, et al. Among authors: cervetti g. Leuk Lymphoma. 2025 Jun;66(6):1111-1120. doi: 10.1080/10428194.2025.2456094. Epub 2025 Jan 21. Leuk Lymphoma. 2025. PMID: 39835889
36 results